Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Scotiabank Downgrades Continental Resources to Sector Perform

Scotiabank Downgrades Continental Resources to Sector Perform

Scotiabank analyst Paul Cheng downgrades Continental Resources (NYSE:CLR) from Sector Outperform to Sector Perform.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Scotiabank analyst Paul Cheng downgrades Continental Resources (NYSE:CLR) from Sector Outperform to Sector Perform.

News
Tech

The Reason Behind Sam Altman’s Ouster From OpenAI Could Be Something Elon Musk Has Been Complaining About

By Rounak Jain

November 18, 2:00 AM

The reason behind Sam Altman's surprise ouster from OpenAI could be something that Elon Musk has long been complaining about.

ABNB

Analyst Ratings

Where Fortrea Holdings Stands With Analysts

By Benzinga Insights

January 4, 10:00 AM

Fortrea Holdings (NASDAQ:FTRE) has been analyzed by 5 analysts in the last three months, revealing a diverse range…

FTRE

Dogecoin, Pepe, Bonk Lead Memecoin Rally After Week-Long Corrective Action

By Aniket Verma

June 12, 11:59 PM

The memecoin market erupted on Wednesday, following impressive gains by Dogecoin, Pepe, and Bonk.

$BONK

AngioDynamics Announces Sale Of Dialysis Product Portfolio And BioSentry Product To Merit Medical Systems For $100M; Announces Preliminary FY23 Net Sales In The Range Of $338M-$339M Vs $338.83M Est.

By Happy Mohamed

June 8, 4:03 PM

Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on

ANGO

Scotiabank Downgrades Continental Resources to Sector Perform

Related Posts

The Reason Behind Sam Altman’s Ouster From OpenAI Could Be Something Elon Musk Has Been Complaining About

Where Fortrea Holdings Stands With Analysts

Dogecoin, Pepe, Bonk Lead Memecoin Rally After Week-Long Corrective Action

AngioDynamics Announces Sale Of Dialysis Product Portfolio And BioSentry Product To Merit Medical Systems For $100M; Announces Preliminary FY23 Net Sales In The Range Of $338M-$339M Vs $338.83M Est.